IMMEDIATE IMMUNITY

Welcome to the Brand page for “IMMEDIATE IMMUNITY”, which is offered here for Biochemicals, monoclonal antibodies and fragments thereof, for clinical, diagnostic and therapeutic use for the treatment or prevention of infectious diseases, biowarfare exposure, inflammatory diseases, immune diseases, and genetic diseases; cell lines for clinical, diagnostic and therapeutic use for the treatment or prevention of infectious diseases, biowarfare exposure, inflammatory diseases, immune diseases, and genetic diseases; vaccines, therapeutic vaccines, polypeptide vaccines, live vaccines, viral vaccines, nucleic acid vaccines, vaccines containing antibodies, polypeptides, protein and nucleic acids, vaccine recipients, vaccine carriers, and vaccines adjuvants;biochemicals, monoclonal antibodies and fragments thereof, for research, development and manufacturing of pharmaceuticals; cell lines for use in the manufacture of pharmaceuticals; biochemical products for use in the development of vaccines, therapeutic vaccines, polypeptide, viral and nucleic acids vaccines, antibodies, polypeptides, protein and nucleic acids for vaccine use; and vaccine excipients, vaccine carriers, and vaccine adjuvants for medical science;scientific, pharmaceutical and biological product development consultation, development consultation for vaccines and vaccine-related products; pharmaceutical and biological product development for others; vaccine and immunotherapy research and development; pharmaceutical, biomedical and biotechnological development of therapeutic vaccines and antibody-based products;.

Its status is currently believed to be active. Its class is unavailable. “IMMEDIATE IMMUNITY” is believed to be currently owned by “Xenerex Biosciences”.

Owner:
XENEREX BIOSCIENCES
Owner Details
Description:
Biochemicals, monoclonal antibodies and fragments thereof, for clinical, diagnostic and therapeutic use for the treatment or prevention of infectious diseases, biowarfare exposure, inflammatory diseases, immune diseases, and genetic diseases; cell lines for clinical, diagnostic and therapeutic use for the treatment or prevention of infectious diseases, biowarfare exposure, inflammatory diseases, immune diseases, and genetic diseases; vaccines, therapeutic vaccines, polypeptide vaccines, live vaccines, viral vaccines, nucleic acid vaccines, vaccines containing antibodies, polypeptides, protein and nucleic acids, vaccine recipients, vaccine carriers, and vaccines adjuvants;Biochemicals, monoclonal antibodies and fragments thereof, for research, development and manufacturing of pharmaceuticals; cell lines for use in the manufacture of pharmaceuticals; biochemical products for use in the development of vaccines, therapeutic vaccines, polypeptide, viral and nucleic acids vaccines, antibodies, polypeptides, protein and nucleic acids for vaccine use; and vaccine excipients, vaccine carriers, and vaccine adjuvants for medical science;Scientific, pharmaceutical and biological product development consultation, development consultation for vaccines and vaccine-related products; pharmaceutical and biological product development for others; vaccine and immunotherapy research and development; pharmaceutical, biomedical and biotechnological development of therapeutic vaccines and antibody-based products;
Categories: BIOCHEMICALS